Use of Intravenous Immunoglobulin G in Comprehensive Treatment of Covid-19 Severe Patients. Series of Clinical Cases

Abstract

Introduction. The incidence of COVID-19 continues to rise rapidly worldwide, leading to significant socio-economic damage to health and economic systems.Objective. To determine the effectiveness of intravenous immunoglobulin G (IVIG) in combination with a basic therapy in severe COVID-19.Materials and methods. A retrospective cohort study of 8 case histories of patients with severe COVID-19 for the period from 27.08.2020 to 20.03.2021 was conducted in the intensive care unit (ICU) of the infectious diseases department of the Municipal Non-Profit Enterprise «Kyiv City Clinical Hospital №17» (MNE KCCH №17).Results and discussions. During the period from 27.08.20 to 20.03.21 in the intensive care unit (ICU) of the infectious department of the Municipal Non-Profit Enterprise «Kyiv City Clinical Hospital №17» (MNE KCCH №17) there were 163 patients, of whom 79 died and the mortality rate was 48.4%. The mean age of patients was 63.5 ± 12.9 years (19 to 95 years). The mean age of death was 66.9 ± 9.9 years (40 to 87 years).During the study period, 8 patients received IVIG (5%) together with a basic therapy. The mean age of patients was 51.4 ± 14.7 years (from 29 to 69 years). Mortality among patients receiving IVIG was 37.5%.Conclusions. Mortality of patients who received IVIG in addition to a basic therapy was significantly lower compared to patients who received only basic therapy, 37.5% and 48.4%, respectively.